Sanofi Rare Diseases Medical
Fabry Disease
Fabry Disease: Recognizing a Variable Condition
A review of the clinical features and underlying pathology of Fabry disease, with a focus on its heterogeneous clinical presentations and progressive disease course. Information is provided on the nephropathy, cardiovascular, CNS/PNS, skin, ocular, auditory, gastrointestinal, and pulmonary manifestations of Fabry disease
____________________________________________________________________________________________________________________________________
Rare Diseases University
This comprehensive educational initiative is a physician need–oriented, interactive, and virtual platform designed for healthcare professionals around the world who are committed to advancing their knowledge and leadership in rare lysosomal storage diseases.
____________________________________________________________________________________________________________________________________
HCM-Fabry Cardiac Disease Symposium
In this symposium "Highlighting Hypertrophic Cardiomyopathy and Fabry Cardiac Disease," recorded on November 20, 2020, Dr. Gavin Y. Oudit (University of Alberta, Edmonton, AB, Canada) discussed the following topics:
Cardiac Involvement in Fabry Disease
____________________________________________________________________________________________________________________________________
Review of Screening Results for Fabry Disease in Relation to Hypertrophic Cardiomyopathy
Monitoring Matters – Fabry Disease:
Fabry disease may progress silently before clinical manifestations and irreversible organ damage become evident. Therefore, it is essential to monitor patients carefully in order to not miss the appropriate time for initiation of Fabry-specific multi-organ management.
____________________________________________________________________________________________________________________________________
Genetic Testing and Genetic Counseling:
This clinical monograph summarizes the insights and real-world best practices collected during an Advisory Council Meeting on genetic testing and genetic counseling held in August 2022 with experienced practice providers from across the United States.
____________________________________________________________________________________________________________________________________
Lysosomal Storage Disease Biomarkers:
This clinical monograph summarizes the insights and real-world best practices collected during an Advisory Council Meeting on obtaining and evaluating biomarkers for lysosomal storage disorders held in August 2023 with experienced practice providers from across the United States.
____________________________________________________________________________________________________________________________________
PubVisual: Risk Stratification in FD Using LysoGL3
This PubVisual is a 4 minute graphic summary of van der Veen’s 2023 publication: “Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Lyso-GL-3 Levels”. It provides data on stability of lyso-GL-3 levels across the lifespan in its association with clinical manifestations of Fabry disease (FD) in over 200 patients with FD.
____________________________________________________________________________________________________________________________________
9’59” Science Talk for Fabry Disease – Video Podcast 3 Challenges Experienced in Monitoring Pediatric Patients with Fabry Disease
In the third episode of our US Medical Video Podcast Series, Jerry Walter, Founder and Executive Director of the National Fabry Disease Foundation, and Ms. Dawn Laney, Associate Professor and Director of the Emory Genetic Clinical Trial Center, will discuss the challenges experienced in monitoring pediatric patients with Fabry disease. Mr. Walter will share insights from his experience and explorations as a Patient Advocacy Group Leader.
____________________________________________________________________________________________________________________________________
9’59” Science Talk for Fabry Disease – Video Podcast 2 Challenges in Making the Dx of Fabry Disease
In the second episode of our US Medical Video Pod-Cast Series, Jack Johnson, Executive Director of the Fabry Support and Information Group, and Dr. Daniele Massera, Associate Director of the Hypertrophic Cardiomyopathy (HCM) Program and NYU discuss the challenges families experience during family screening for Fabry disease. Dr. Massera addresses the value of genetic testing in patients with HCM and encourages cardiologists to value pedigree analysis as a high-yield intervention.
____________________________________________________________________________________________________________________________________
9’59” Science Talk for Fabry Disease – Video Podcast 1: Fatigue in Females with Fabry Disease
In this first episode of our new US Medical Video Pod-Cast Series, Julia Alton, Executive Director of the Canadian Fabry Association and Dr. Robert Hopkin, Clinical Geneticist from Cincinnati Children’s Hospital, discuss the burden of Fabry-related fatigue and the impact it has on the lives of females with Fabry disease. Julia and Dr. Hopkin will explore potential pathologies of Fabry-related fatigue in an effort to better understand an aspect of Fabry disease which has such significant impact on the daily quality of life for many women.
____________________________________________________________________________________________________________________________________
Diagnosing Fabry Disease
For more information on testing for Fabry disease, including incidence, patient classification, evaluations for diagnosis, and a selection of laboratories offering both α-GAL A enzyme assay and GLA sequencing, click to open our full testing brochure.
____________________________________________________________________________________________________________________________________
Kidney Panel Testing
This brochure provides information on chronic kidney disease (CKD) as a condition characterized by gradual loss of kidney function over time. Patients with Fabry disease can present with isolated CKD or with CKD in conjunction with additional signs and symptoms such as bradycardia, left ventricular hypertrophy, cardiac arrhythmias, heart failure, strokes, neuropathic and gastrointestinal pain, hearing loss, and angiokeratomas.
____________________________________________________________________________________________________________________________________
Cardiac Gene Panels
This brochure provides information on hypertrophic cardiomyopathy which is a genetic disorder of cardiac myocytes. Patients with Fabry disease can present with isolated HCM or HCM in conjunction with additional signs and symptoms such as bradycardia, cardiac arrhythmias, heart failure, strokes, kidney dysfunction, neuropathic and gastrointestinal pain, hearing loss, and angiokeratomas.
____________________________________________________________________________________________________________________________________
Fabry Disease Biomarker Testing: Lyso-GL3
For information about the Fabry disease biomarker lyso-GL3 (lyso-Gb3), and testing options, please click to see our brochure.
Pacific Stroke Congress
Dr. Robert Hopkin speaks to the vascular complications of Fabry disease in this address to the 2024 Pacific Stroke Conference, “Fabry is a Vascular Disease”. Dr. Hopkin highlights the risks of stroke in males with females with Fabry disease regardless of phenotype and reviews screening recommendations for patients presenting with early cryptogenic stroke.
____________________________________________________________________________________________________________________________________
Fabry Disease Is a Pediatric Disease
In this symposium “Fabry is a Pediatric Disease,” from the WORLD 2023 conference in February 2023, Dr. Robert J. Hopkin (Cincinnati Children's Hospital Medical Center, Cincinnati, OH) discussed the following topics:
Neurological Monitoring
In this excerpt from the Monitoring Matters webinar series “Neurological Monitoring,” Dr. Max Hilz (Icahn School of Medicine at Mount Sinai, New York, NY, USA) focuses on neurological monitoring of patients with Fabry disease.
Sanofi does not review or control the content of non-Sanofi websites. These listings do not constitute an endorsement by Sanofi of information provided by any other organizations.
Concert Genetics
____________________________________________________________________________________________________________________________________
Genetic Home Reference
____________________________________________________________________________________________________________________________________
Fabry Support and Information Group
____________________________________________________________________________________________________________________________________
National Fabry Disease Foundation
____________________________________________________________________________________________________________________________________
National Organization for Rare Disorders
____________________________________________________________________________________________________________________________________
Sanofi Medical Information
____________________________________________________________________________________________________________________________________
Patient Registry
The Fabry Registry, a program sponsored and administered by Sanofi, was created in 2001 to gather information to improve the understanding and evaluate the treatment of Fabry disease. It is the largest patient registry dedicated to Fabry disease.
Because Fabry disease is rare, it can be difficult to collect information about it and its impacts on different people. The Fabry Registry is a global, observational database for gathering this critical information. All people who have Fabry disease are eligible to participate, regardless of whether they are on treatment.
For more information on The Fabry Registry, visit our website.